Global Oligonucleotide CDMO Market Size, Share, Growth & Trends Report Segmented by Service (Contract Manufacturing & Development), Type (ASOs, siRNA), Application (Therapeutic, Research, Diagnostic), End-user (Biopharma Companies), & Regional Forecast to 2031

The oligonucleotide CDMO comprises specialized service providers that offer contract development and manufacturing of synthetic oligonucleotides. These include antisense oligonucleotides (ASOs), small interfering RNA (siRNA), microRNA, aptamers, and other nucleic acid–based therapeutics. These CDMOs offer end-to-end services including sequence design, development, high-purity synthesis to advanced conjugation, analytical characterization, regulatory support and LNP formulation/fill-finish services. Due to the increasing complexity associated with the manufacturing of oligonucleotides and stringent regulatory requirements, biopharma companies are increasingly relying on CDMOs to access technical expertise and scalable GMP-certified manufacturing platforms.

Increasing clinical advancement of RNA-based therapeutics

The expansion of RNA-based drug development is one of the key forces reshaping the oligonucleotide CDMO market. RNA therapeutics/treatments, including antisense and siRNA oligonucleotides, are shifting from experimental stages into late-stage trials and then towards faster commercial approvals. Additionally, there has been a surge in the number of clinical trials using oligonucleotide-based approaches targeting rare genetic disorders, oncology, and infectious diseases over the past decade.

Oligonucleotides directly influence gene expression, often treating conditions that were previously not easily addressed by traditional small molecules or biologics. This capability has expanded their role in precision medicine, where sequence-specific targeting enables highly individualized treatment strategies, such as patient-customized ASOs for rare genetic diseases.

As an increasing number of candidates advance from early-stage trials toward commercialization, the need for dependable manufacturing partners has become more evident. At the same time, clinical progression to later phases places greater emphasis on rigorous process control and consistent product quality, particularly as therapies approach regulatory approval. To meet these requirements, manufacturers are increasingly adopting improved synthesis materials and optimized workflows that enhance efficiency and reproducibility.

To learn more about this report, download the PDF brochure

Rising outsourcing among emerging biopharma companies

One of the notable trends in the oligonucleotide CDMO market is the increasing outsourcing adopted by small and mid-sized biotechnology firms, which are advancing oligonucleotide-based therapeutics due to a lack of infrastructure required for large-scale and GMP-compliant production. Also, there is an expanding RNA therapy pipeline, which is further increasing the number of companies seeking external development and manufacturing support. As a result, outsourcing has become a practical, necessary route for progressing candidates through clinical development.

In-house development of oligonucleotide manufacturing capabilities is not feasible for smaller firms, especially as it requires substantial capital investment, technical expertise, strong regulatory compliance, and the ability to handle hazardous materials. In addition, relying on traditional synthesis approaches can introduce efficiency constraints, creating further challenges for companies attempting to scale production independently. For many emerging firms, partnering with CDMOs offers a more flexible and resource-efficient solution, thereby allowing them access to advanced manufacturing technology.

Beyond cost considerations, outsourcing provides access to advanced synthesis, purification, and conjugation technologies to improve delivery. Many CDMOs have incorporated upgraded infrastructure that overcomes manufacturing bottlenecks by enabling scale-up, maintaining high-purity standards, and ensuring compliance with evolving regulatory guidelines. Further, the growing requirements around scalability and product quality are reinforcing the preference for outsourcing to experienced partners with established technical capabilities.

Expansion of conjugated and modified oligonucleotides

A notable development in the market is the increasing focus on chemically modified and conjugated oligonucleotides. Techniques such as lipid conjugation, peptide attachment, and backbone modifications are being explored to improve stability, enhance delivery, and increase therapeutic efficacy. This shift towards complexity is fundamentally reshaping CDMO capabilities. Manufacturing of these advanced oligonucleotides requires specialized expertise in conjugation chemistry, complex analytical testing, and stringent process control. As a result, manufacturers are expanding infrastructure and investing in specialized GMP-compliant production lines and quality systems tailored to complex oligonucleotide formats. As therapeutic designs become more sophisticated, CDMOs are evolving from simple contract manufacturers into integrated partners. These partners provide end-to-end development, covering sequence optimization, conjugation strategies, analytical method validation, and commercial-scale production.

To learn more about this report, download the PDF brochure

Type Segment Outlook

The global oligonucleotide CDMO market is categorized by type into Antisense Oligonucleotides (ASOs), Small Interfering RNA (siRNAs), and other oligonucleotides. ASO leads the market due to high demand and success rate in the treatment of cancer, rare genetic and neurologic disorders, among others. This is further strengthened by the growing number of clinical trials and their commercialization, which require high-purity GMP-certified synthesis and scalable manufacturing. However, the siRNA segment is expected to grow faster in the coming years due to advances in GalNAc-conjugate delivery systems, superior efficacy, higher potency and expanding applications in the treatment of chronic diseases. Other nucleotides, including mRNA, gRNA, and aptamers, are gaining traction due to their increasing adoption in gene-editing therapies, further expanding the therapeutic scope of oligonucleotide-based approaches.

Regional Outlook: North America is expected to hold a major share in the global oligonucleotide CDMO market

North America holds the largest share of the global oligonucleotide CDMO market, with the strong presence of key market players in this region, the availability of advanced healthcare infrastructure, and the early adoption of advanced treatments. Other factors further contributing to the large share of the region in this market include a growing number of investments in R&D and regulatory support that facilitate rapid drug approval. Europe follows closely, with growth driven by rising research activity, supportive regulatory frameworks, and noted for its strong specialized manufacturing capabilities in countries like Germany and Switzerland. However, the Asia Pacific is the fastest-growing region, with increasing investments in biotechnology, rising demand for outsourcing, and competitive manufacturing costs.

Competitive Landscape Analysis

The global oligonucleotide CDMO market is marked by the presence of established and emerging market players such as Bachem Holding AG (Switzerland); Agilent Technologies (US); Lonza Group (Switzerland); Thermo Fisher Scientific (US); WuXi AppTec (China); ST Pharm Co., Ltd. (South Korea); Eurofins Scientific (Luxembourg); PolyPeptide Group (Switzerland); Ajinomoto Bio-Pharma Services (Japan); Aurigene Pharmaceutical Services Ltd; and  Kaneka Eurogentec S.A (Belgium), among others.

Get a sample report for competitive landscape analysis

Growth strategies adopted by players to establish their foothold in the global oligonucleotide CDMO market

Players operating in this market are adopting various growth strategies such as new product launches and approvals, acquisitions, expansions, and strategic partnerships, agreements, and collaborations, to garner market share. For instance,

• In November 2024, WuXi AppTec opened a new R&D center in Changzhou, China, to enhance process development for oligonucleotides, peptides, and complex conjugates. The facility strengthens integration between early-stage development and manufacturing, improving efficiency and scalability
• In November 2024, Lonza announced it will invest in additional bioconjugation capabilities at its Visp (CH) site by adding two multipurpose 1,200L manufacturing suites and infrastructure, which will double its capacity for launch and commercial supply of bioconjugates and address growing market demand
• In July 2024, Agilent Technologies announced the acquisition of BIOVECTRA for $925 million, expanding its end-to-end CDMO capabilities in oligonucleotides and CRISPR therapeutics while adding fill-finish, mRNA, pDNA, and lipid nanoparticle formulation expertise to support advanced modalities and gene-editing technologies

Report Scope

Global Oligonucleotide CDMO Market Segmentation

This report by Medi-Tech Insights provides the size of the global oligonucleotide CDMO market at the regional- and country-level from 2024 to 2031. The report further segments the market based on service, type, application, and end user.

Market Size & Forecast (2024-2031), By Service, USD Billion

• Contract Manufacturing
• Clinical
• Commercial
• Contract Development

Market Size & Forecast (2024-2031), By Type, USD Billion

• Antisense Oligonucleotides
• Small Interfering RNA
• Others

Market Size & Forecast (2024-2031), By Application, USD Billion

• Therapeutic
• Research
• Diagnostic
• Others

Market Size & Forecast (2024-2031), By End User, USD Billion

• Pharmaceutical Companies
• Biotechnology Companies
• Others

Market Size & Forecast (2024-2031), By Region, USD Billion

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Rest of Asia Pacific
• Latin America
• Middle East & Africa